Efficacy and Safety of Alteplase Use for Venous Catheter Thrombosis in Pediatric Patients―a Single Center Study
- 1 January 2026
- journal article
- Published by Wiley in Pediatrics International
- Vol. 68 (1)
Abstract
Background: Urokinase is used as a thrombolytic agent to treat catheter thrombosis. However, since 2022, the supply of urokinase has diminished, and we have been using alteplase as an alternative, although its use for treating catheter thrombosis is off‐label in Japan. Methods: We performed a single‐center, retrospective study on pediatric patients with central venous catheters (CVCs), peripherally inserted central catheters (PICCs), and central venous ports (CVPs) who received alteplase for catheter thrombosis at our facility (May 2023–October 2025). Treatment involved filling the catheter (volume: 1–1.5 mL) with 600,000 U/mL (1 mg/mL) of alteplase solution and leaving it for approximately 40 min. Efficacy was evaluated as follows: (1) success on the first dose, (2) success after two or three doses, or (3) no success. (1) and (2) were defined as effective. Results: We evaluated 84 alteplase administrations in 31 patients (CVCs: 47, PICCs: 27, CVPs: 10). Success on the first dose was achieved in 55% of cases and success after two or three doses in 20% of cases, resulting in an overall efficacy rate of 75% (CVCs: 72%, PICCs: 93%, CVPs: 40%). No adverse events were observed. Conclusions: Alteplase was generally effective for treating catheter thrombosis. However, results suggest that it is less effective in CVPs than in CVCs and PICCs, and a larger sample size is necessary for confirmation. We recommend that alteplase be approved for treating catheter thrombosis in Japan.Keywords
This publication has 13 references indexed in Scilit:
- Comparative efficacy of alteplase and urokinase in pharmacomechanical thrombolysis of permanent double lumen hemodialysis catheters in childrenPediatric Nephrology, 2025
- Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trialHemodialysis International, 2016
- Alteplase for the Treatment of Central Venous Catheter Occlusion in Children: Results of a Prospective, Open-label, Single-arm Study (The Cathflo Activase Pediatric Study)Journal of Vascular and Interventional Radiology, 2006
- Alteplase for Treatment of Occluded Peripherally Inserted Central Catheters: Safety and Efficacy in 240 PatientsJournal of Vascular and Interventional Radiology, 2004
- Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Function to Occluded Central Venous Catheters in Pediatric PatientsJournal of Pediatric Hematology/Oncology, 2003
- Venous Port Salvage Utilizing Low Dose tPACardioVascular and Interventional Radiology, 2002
- Treatment of Occluded Central Venous Catheters with Alteplase: Results in 1,064 PatientsJournal of Vascular and Interventional Radiology, 2002
- Use of Tissue Plasminogen Activator (rt-PA) in Young Children With Cancer and Dysfunctional Central Venous CathetersJournal of Pediatric Hematology/Oncology, 2002
- Recombinant Tissue Plasminogen Activator (Alteplase) for Restoration of Flow in Occluded Central Venous Access Devices: A Double-Blind Placebo-Controlled Trial—The Cardiovascular Thrombolytic to Open Occluded Lines (COOL) Efficacy TrialJournal of Vascular and Interventional Radiology, 2001
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995